FindMyKOL
Clinical trialNCT02888665CompletedPhase 1/2Interventional

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

NCT02888665 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies Doxorubicin and Pembrolizumab in Sarcoma. The registry lists an enrollment of 37 participants at 1 site in 1 country. The registry lists a start date of 5 Dec 2016 and a primary completion date of 17 Mar 2020. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02888665
FieldValue
Registry IDNCT02888665
StatusCompleted
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment37
Registered sites1
Countries1
ConditionsSarcoma
DrugsDoxorubicin and Pembrolizumab
Start5 Dec 2016
Primary completion17 Mar 2020
Study completion9 Oct 2020
Last update posted26 May 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the side effects and best dose of doxorubicin hydrochloride when given together with pembrolizumab and to see how well they work in treating patients with sarcoma that have spread to other parts of the body or that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin hydrochloride together with pembrolizumab may work better in treating patients with sarcoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02888665

Each answer restates registry values shown on this page.

What is NCT02888665?

NCT02888665 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Doxorubicin and Pembrolizumab in Sarcoma.

Who leads NCT02888665?

The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.

Where does NCT02888665 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02888665 study?

The registered drug and biological interventions are Doxorubicin and Pembrolizumab.

When did NCT02888665 end?

The registry lists a primary completion date of 17 Mar 2020 and a study completion date of 9 Oct 2020. The sponsor last updated the record on 26 May 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.